Sagimet Biosciences Inc/$SGMT

1D1W1MYTD1Y5YMAX

About Sagimet Biosciences Inc

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
Ticker
$SGMT
Sector
Health
Primary listing
NASDAQ
Employees
16
Headquarters
San Mateo, United States
Website
www.sagimet.com

SGMT Metrics

BasicAdvanced
$618M
-
-$1.25
3.40
-

Bulls say / Bears say

Denifanstat has already met all primary and secondary endpoints in a 12-week Phase 3 acne study in China, with generally good tolerability and sustained improvements reported in the long-term extension. That gives Sagimet useful clinical validation before its US pivotal trial. (Sagimet Biosciences)
The FDA has cleared the US Phase 3 acne programme, and Sagimet expects to start enrolling the approximately 800-patient AURORA trial in the fourth quarter of 2026. The trial is designed to support an NDA after the 12-week controlled phase, creating a clear near-term catalyst. (Sagimet Biosciences, MarketScreener)
Sagimet reported that denifanstat combined with resmetirom was generally well tolerated in a Phase 1 study, while total and LDL cholesterol fell rapidly after two weeks. The combination could reopen a larger MASH opportunity if the company secures non-dilutive funding for later-stage trials. (GlobeNewswire, Sagimet Biosciences)
The US AURORA study will include many adolescents, and its younger population and potentially lower treatment adherence may make the Chinese efficacy results harder to reproduce. Goldman Sachs said the trial risk may not be fully reflected in the valuation. (GuruFocus, MarketScreener)
Sagimet remains pre-revenue, loss-making and dependent on external financing, despite reporting $257.6 million of cash, cash equivalents and marketable securities at 30 June 2026. It says additional capital will be needed until its products generate sufficient revenue, leaving investors exposed to further dilution or financing risk. (SEC filing)
The company has prioritised acne and will not undertake further MASH clinical development until it secures non-dilutive funding. This limits near-term progress in a potentially valuable indication and leaves the MASH investment case dependent on an uncertain funding outcome. (Sagimet Biosciences)
Data summarised monthly by Lightyear AI. Last updated on 24 Sept 2026.

SGMT News

AllArticlesVideos

Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data

MarketBeat1 month ago

Funds containing SGMT

AllUSDGBPEUR
Funds
Fund name
Fund size
$SGMT weighting
iShares Nasdaq US Biotechnology$BTEC
$1.2B0.04%
iShares Nasdaq US Biotechnology£BTEK
£865M0.04%
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.02%
SPDR Russell 2000 US Small Cap£R2SC
£4.1B0.02%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.